About Hyloris
Hyloris is a company based in Minneapolis (United States) founded in 2014. Hyloris has raised $16.29 million across 1 funding round from investors including Nomainvest, Noshaq and Saffelberg Investments. The company has 14 employees as of December 31, 2021. Hyloris offers products and services including Maxigesic IV and Sotalol IV. Hyloris operates in a competitive market with competitors including Portola Pharma, Cellino, Arrakis Therapeutics, Flexion Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Minneapolis, United States
- Employees 14 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.29 M (USD)
in 1 rounds
-
Latest Funding Round
$16.29 M (USD), Series B
Apr 30, 2020
-
Investors
Nomainvest
& 2 more
-
Employee Count
14
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hyloris
Hyloris offers a comprehensive portfolio of products and services, including Maxigesic IV and Sotalol IV.
Intravenous drug for pain relief in medical settings.
Intravenous treatment for heart rhythm disorders.
People of Hyloris
Unlock access to complete
Funding Insights of Hyloris
Hyloris has successfully raised a total of $16.29M through 1 strategic funding round. The most recent funding activity was a Series B round of $16.29 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hyloris
Hyloris has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Nomainvest, Noshaq and Saffelberg Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Noel family investments are managed by this family office.
|
Locked | Locked | Locked |
Investor details for Hyloris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hyloris
Investment portfolio details for Hyloris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hyloris
Detailed financials for Hyloris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hyloris Comparisons
Peer comparison for Hyloris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hyloris
Hyloris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, Cellino, Arrakis Therapeutics, Flexion Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
Detailed competitors of Hyloris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hyloris
Complete news archive for Hyloris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hyloris
Hyloris was founded in 2014 and raised its 1st funding round 6 years after it was founded.
Hyloris is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Stijn Van Rompay is the current CEO of Hyloris.
Hyloris is a funded company, having raised a total of $16.29M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Hyloris is 14.
Hyloris was founded in 2014 and is based in Minneapolis, United States. Focus is placed on pharmaceutical development for rare and orphan conditions. The pipeline includes Sotalol IV for arrhythmia, P-004 for inherited bleeding disorders, P-002 for pain management, and P-006 for oral mucositis. Generics such as Podofilox for vaginal warts and Dinoprostone for labor induction are also pursued in the sector.
Hyloris's top competitors include Flexion Therapeutics, Tenaya Therapeutics and Cellino.
Hyloris offers Maxigesic IV and Sotalol IV.
Hyloris has 3 investors. Key investors include Nomainvest, Noshaq, and Saffelberg Investments.